Case report: Visceral leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient

American Journal of Tropical Medicine and Hygiene

Volumn 83, Issue 1, 2010, Pages 10-12

  Barragán, Patricia ^a   López Velez, Rogelio ^b   Olmo, Montserrat ^a   Podzamczer, Daniel ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ITRACONAZOLE; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; DRUG DERIVATIVE; PHOSPHORYLCHOLINE;

ADULT; AMASTIGOTE; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CD4 LYMPHOCYTE COUNT; DRUG TREATMENT FAILURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LEISHMANIA; LYMPH NODE BIOPSY; MALE; OTOTOXICITY; RELAPSE; VIRUS LOAD; VISCERAL LEISHMANIASIS; AIDS RELATED COMPLEX; DRUG SENSITIVITY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEISHMANIASIS; OPPORTUNISTIC INFECTION; PATHOPHYSIOLOGY; RECURRENT DISEASE; SKIN LEISHMANIASIS; TREATMENT FAILURE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; HIV; HIV INFECTIONS; HIV-1; HUMANS; ITRACONAZOLE; LEISHMANIASIS; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; OPPORTUNISTIC INFECTIONS; PARASITIC SENSITIVITY TESTS; PAROMOMYCIN; PHOSPHORYLCHOLINE; RECURRENCE; TREATMENT FAILURE;

EID: 77954590039     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2010.09-0594     Document Type: Article

References (20)

1. de La Rosa R, Pineda JA, Delgado J, 2002. Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy. J Clin Microbiol 40: 762-767. (Pubitemid 34208620)
2. Alvar J, Aparicio P, Aseffa A, 2008. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 21: 334-359. (Pubitemid 351555511)
3. Sundar S, 2001. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 6: 849-854. (Pubitemid 33010870)
4. Sundar S, Rai M, 2005. Treatment of visceral leishmaniasis. Expert Opin Pharmacother 6: 2821-2829.
5. Troya J, Casquero A, Refoyo E, 2008. Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients. Scand J Infect Dis 40: 78-80.
6. Manfredi R, Marinacci G, Calza L, 2008. Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine and paromomycin administration. Int J Antimicrob Agents 31: 590-592.
7. Soto J, Soto P, 2006. Oral miltefosine to treat leishmaniasis. Biomedica (Bogota) 26: 207-217.
8. Davidson RN, den Boer M, Ritmeijer K, 2009. Paromomycin. Trans R Soc Trop Med Hyg 103: 653-660.
9. Sundar S, Jha TK, Thakur CP, 2007. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 356: 2571-2581. (Pubitemid 46961002)
10. Jha TK, Olliaro P, Thakur CP, 1998. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ 316: 1200-1205. (Pubitemid 28171334)
11. Lafeuillade A, Chaffanjon P, Delbeke E, 1992. Maintenance itraconazole for visceral leishmaniasis in HIV infection. Am J Med 92: 449.
12. Chunge CN, Owate J, Pamba HO, 1990. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans R Soc Trop Med Hyg 84: 221-225. (Pubitemid 20172009)
13. Thakur CP, Olliaro P, Gothoscar S, 1992. Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)- antimonial combinations, a pilot study in Bihar, India. Trans R Soc Trop Med Hyg 86: 615-616. (Pubitemid 23012903)
14. Thakur CP, Bhowmick S, Dolfi L, 1995. Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: a randomized dose-finding clinical trial. Trans R Soc Trop Med Hyg 89: 219-223.
15. Thakur CP, Kanyok TP, Pandey AK, 2000. A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 94: 429-431.
16. Seaman J, Pryce D, Sondorp HE, 1993. Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J Infect Dis 168: 715-720. (Pubitemid 23254293)
17. Pintado V, Martín-Rabadán P, Rivera ML, 2001. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore) 80: 54-73.
18. Davidson RN, 1998. Practical guide for the treatment of leishmaniasis. Drugs 56: 1009-1018.
19. Béchade D, Seurat L, Discamps G, 1996. Multiple digestive involvement in visceral leishmaniasis in a patient with HIV infection: favourable course with itraconazole. Rev Med Interne 17: 234-237. (Pubitemid 26133013)
20. Angarano G, Maggi P, Coppola SL, 1998. Itraconazole as maintenance therapy for visceral leishmaniasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis 17: 365-367. (Pubitemid 28379328)